MTI-TSI partnership aims for ingredient innovations
“The goals for MTI and TSI are to collaborate and create clinically tested and proven ingredients protected by manufacturing expertise, knowhow or process patents, composition and use patents, brands and trademarks,” said Shawn Baier, MTI chief operating officer.
MTI’s first product, beta-hydroxy-beta-methylbutyrate (HMB), is supported by numerous published studies that report the benefits to both casual and competitive athletes to improve their strength and endurance as well as having applications in general health and medical nutrition, said the company.
TSI Health Sciences has offers products and services in two primary areas – integrated high-quality supply chain value, and ingredient innovation.
“The strategic partnership between MTI and TSI allows both parties to develop and commercialize products with shared resources, talent and vision, leading to greater long-term business value for both companies, as well as bringing a vast range of new, innovative ingredients to the marketplace faster and more effectively,” said Larry Kolb, TSI Health Sciences U.S. operations president.
